The article has great delight in revealing that an up-to-the-minute guideline review for the treatment of CLL, published online July 21 in the Journal of Clinical Oncology by a team of experts from Ohio State University in Columbus, was out of date two days later!
Neil
Photo: Some crystal balls for those trying to work out what treatment they will eventually receive; water droplets from a heavy fog on grass blades.
Written by
AussieNeil
Partner
To view profiles and participate in discussions please or .
These drugs are protected, at least in the U.S. under the Orphan Drug Act which gives them a protected market to some extent and other benefits to develop and bring drugs to market. There isn't much competition. CLL is, I believe, the only cancer listed under the Rare and Neglected Diseases.
The patent is coming off Rituxan in 2018 in the U.S.. It will be interesting to see what downward pressure will be brought on costs as 'biosimilars' hit the market... it came off in 2013 in Europe.
Imbruvica (ibrutinib) will be starting the funding recommendation process in Canada later this fall and it will be interesting to see what the costs implication are. the funding request is...
'For the treatment of patients with CLL/SLL with or without deletion 17p who have received at least one prior therapy and are not considered appropriate for treatment or re-treatment with a purine analog'
Limited to second line, basically for patients that can't have fludarabine etc...
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.